AstraZeneca prepares to live with the IRA, shifting focus of arguments to orphan drug changes
NEW YORK — AstraZeneca may be getting ready to live with the Inflation Reduction Act.
On Friday morning, CEO Pascal Soriot told reporters that the drugmaker is most focused on getting the 2022 law adjusted, not invalidated. His comments are the most direct yet from a major pharma CEO about a future in which the IRA is not fully overturned by the courts, as several drugmakers have sued to try and do.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.